SCHEMBL996777

SCHEMBL996777

Nc1ccccc1-c1nccs1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.53
ADORA2A P29274 2/20 0.49
ADORA1 P30542 2/20 0.49
ALDH1A1 P00352 6/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HSP90AA1 P07900 1/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KDM4E B2RXH2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL7297431 0.90 HDAC2 (0.49) PDPK1ADORA2AADORA1ALDH1A1HSP90AA1
SCHEMBL5692672 0.85 PDPK1 (0.64) PDPK1ADORA2AADORA1ALDH1A1HSP90AA1
SCHEMBL11159480 0.85 PDPK1 (0.46) PDPK1ADORA2AADORA1ALDH1A1HSP90AA1
SCHEMBL1951149 0.83 PDPK1 (0.61) PDPK1ADORA2AADORA1ALDH1A1HSP90AA1
SCHEMBL20689616 0.82 PDPK1 (0.43) PDPK1ADORA2AADORA1ALDH1A1HSP90AA1
SCHEMBL20092688 0.81 MGAM (0.42) PDPK1ADORA2AADORA1ALDH1A1HSP90AA1
SCHEMBL20609434 0.81 PDPK1 (0.56) PDPK1ADORA2AADORA1ALDH1A1HSP90AA1
SCHEMBL1047236 0.80 PDPK1 (0.53) PDPK1ADORA2AADORA1ALDH1A1RAB9A
SCHEMBL31055003 0.79 PDPK1 (0.52) PDPK1ADORA2AADORA1ALDH1A1HSP90AA1
SCHEMBL3663189 0.78 PDPK1 (0.47) PDPK1ADORA2AADORA1ALDH1A1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024035207-A1 ANTI-CORROSIVE CAPSULE, MANUFACTURING METHOD THEREFOR, BRAKE PAD, AND MANUFACTURING METHOD THEREFOR 성균관대학교산학협력단 2024-02-15 WO claimed
WO-2023204651-A1 BRAKE PAD COMPRISING ANTI-CORROSION ADDITIVE AND METHOD FOR MANUFACTURING SAME 성균관대학교산학협력단 2023-10-26 WO claimed
EP-0871619-B1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMA (US) 2002-11-06 EP claimed
US-6288091-B1 COMPOUNDS SUCH AS 2,2,2-TRICHLOROETHYL N-(4-(2-AMINO-4-THIAZOLYL)-PHENYL)CARBAMATE THAT INHIBIT THE HERPES HELCASE-PRIMASE ENZYME COMPLEX BOEHRINGER INGELHEIM LTD. (CA) 2001-09-11 US claimed
EP-0871619-A1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 1998-10-21 EP claimed
WO-1997024343-A1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1997-07-10 WO claimed
WO-1987002273-A1 SEPARATION PROCESS THE BRITISH PETROLEUM COMPANY P.L.C. (GB) 1987-04-23 WO claimed
JP-4204648-A None JP disclosed
US-20250326725-A1 PI4-Kinase Inhibitors and Methods of Using the Same UNIV LELAND STANFORD JUNIOR (US) 2025-10-23 US disclosed
US-12415788-B2 PI4-kinase inhibitors and methods of using the same THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2025-09-16 US disclosed
EP-3419980-B1 PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY UNIV LELAND STANFORD JUNIOR (US) 2025-01-01 EP disclosed
WO-2024155066-A1 ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODY WITH IMPROVED BLOOD-BRAIN-BARRIER PERMEABILITY, AND MULTISPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION USING SAME 주식회사 시그널바이오 2024-07-25 WO disclosed
WO-2024035207-A1 ANTI-CORROSIVE CAPSULE, MANUFACTURING METHOD THEREFOR, BRAKE PAD, AND MANUFACTURING METHOD THEREFOR 성균관대학교산학협력단 2024-02-15 WO disclosed
EP-0315178-A2 Process for producing a urethane and a carbonic acid ester MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1989-05-10 EP disclosed
EP-0263020-A1 4-Phenyl thiazole derivatives LABORATOIRE L. LAFON Société anonyme dite: (FR) 1988-04-06 EP disclosed
WO-1987002273-A1 SEPARATION PROCESS THE BRITISH PETROLEUM COMPANY P.L.C. (GB) 1987-04-23 WO disclosed
EP-0062825-B1 WATER-SOLUBLE TRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR USE BAYER AG (DE) 1987-03-11 EP disclosed
EP-0062825-A2 Water-soluble triazine compounds, their preparation and their use BAYER AG (DE) 1982-10-20 EP disclosed
EP-0021806-A1 2,3-Dihydro-imidazo (2,1-b) benzothiazole derivatives and pharmaceutical compositions containing them JANSSEN PHARMACEUTICA N.V. (BE) 1981-01-07 EP disclosed
EP-0015361-A1 Cumarinic pigments, process for their preparation and their use Montedison S.p.A. (IT) 1980-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326725-A1 PI4-Kinase Inhibitors and Methods of Using the Same PI4KB, PI4KA, PI4K2A PDPK1 43/4885ADORA2A 3328/4885ADORA1 3618/4885
US-12415788-B2 PI4-kinase inhibitors and methods of using the same PI4KB, PI4KA, PI4K2A PDPK1 43/4885ADORA2A 3328/4885ADORA1 3618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.